Sector News

After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact

February 14, 2021
Life sciences

Last year, AbbVie decided to walk away from a pact with gene editing biotech Editas that was originally penned via its new buyout, Allergan.

Now, the Big Pharma is back in the CRISPR biotech game, signing up to a new deal with Editas’ rival Caribou Biosciences, although this research deal goes further.

AbbVie is tapping Caribou’s CRISPR genome editing platform to engineer CAR-T cells to withstand the so-called host immune attack, which would enable the development of the next generation of “off-the-shelf” cellular therapies to benefit a broader patient population. These would also be quicker and easier than traditional CAR-T therapies to make and use.

Its original deal with Editas, via Allergan, was made in 2017 and was worth $90 million for a CRISPR research pact that focused on ocular disorders but not on CAR-T.

AbbVie clearly had other plans, canning that deal in August last year and choosing Caribou instead. The deal sees just $40 million go to the biotech upfront, with a modest $300 million in biobucks also on the table as well as royalties should any treatments grab approvals.

The pact will see AbbVie use Caribou’s next-generation Cas12a CRISPR hybrid RNA-DNA genome editing and cell therapy tech to research and develop two new CAR-T cell therapies directed to targets “specified by AbbVie,” though not in its release, which was light on target details; most CAR-Ts, however, are being directed against common forms of blood cancer.

Caribou, meanwhile, will conduct certain preclinical research, development and manufacturing activities for the collab programs, and AbbVie will reimburse Caribou for its efforts. AbbVie also holds on to an option to pay a fee to expand the pact to include up to an additional two CAR-T cell therapies.

by Ben Adams

Source: fiercebiotech.com

comments closed

Related News

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.

November 19, 2022

Sequana announces results from study of direct sodium removal

Life sciences

Sequana, a company focusing on liver disease, heart failure and cancer has announced positive top-line results from SAHARA – the phase 2a study using its first-generation direct sodium removal (DSR) product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients confirmed long-lasting clinical benefits.